OST-HER2

Rockville, Maryland, June 26, 2026 OS Animal Health announced the peer-reviewed publication of Phase 2 clinical trial results evaluating...

NEW YORK and ROCKVILLE, Md., May 29, 2026 OS Therapies announced the publication of four scientific articles focused on...

NEW YORK, New York, April 30, 2026 OS Therapies announced that the European Medicines Agency (EMA) has initiated a...

NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...

New York, March 27, 2026 OS Therapies has achieved a significant regulatory milestone by securing meetings with multiple global...

NEW YORK, NY — December 5, 2025 — OS Therapies Inc. announced two major regulatory milestones advancing its lead...

Dateline: November 17, 2025 — New York, NYOS Therapies reported its third-quarter 2025 financial results and issued a comprehensive...

New York, NY – October 10, 2025 – OS Therapies Inc. has announced statistically significant positive final results from...